Treg Cell Therapy Platform

About RegCell

RegCell is a private, pre-clinical stage biotech developing Treg-based cell therapies to restore immune self-tolerance in autoimmune diseases. Founded on the pioneering work of Dr. Shimon Sakaguchi, who discovered Tregs, the company aims to create durable, disease-modifying treatments that avoid the broad immunosuppression of current standards. Led by a seasoned executive team with deep experience in drug development and corporate strategy, RegCell is positioned to advance a novel therapeutic platform in a large and underserved market.

About TCBalance Biopharmaceuticals

TCBalance Biopharmaceuticals is a private, preclinical-stage biotech developing a modular platform for regulatory T cell (Treg) therapies targeting autoimmune diseases, transplant rejection, and other immune disorders. The company's strategy involves a stepwise approach, beginning with autologous 'bridging' therapies and progressing towards allogeneic, multitasking Treg products. Led by a founding team with deep expertise in immunology and cell therapy, TCBalance is pursuing strategic collaborations, such as its partnership with Pirche AG, to advance its technology. The company operates in a high-value market with significant unmet need but faces typical biotech risks related to clinical development and competition.

Therapeutic Areas